Facing Opioids in the Shadow of the HIV Epidemic

With two colleagues, Sim Kimmel MD and Jennifer Flynn Walker, I recently wrote a letter to the editor of the New England Journal of Medicine. It was not published, so I include the text below. To the Editor: Parker et al (Jan 3 issue) argue that the community activism crucial to expanding access to antiretroviral therapy is needed now to address the opioid overdose crisis. In particular, … Continue reading Facing Opioids in the Shadow of the HIV Epidemic

‘City Council holds hearing on pedestrian safety’

My latest letter, published in the JP Gazette: Bravo to local heroes such as Councilor Ed Flynn and Boston Transportation Department (BTD) Director of Planning Vineet Gupta. They are making our city streets safer for children, cyclists, and all pedestrians. While officials investigate automated enforcement/ camera systems for speeding and running red lights (which are critically important), a few points bear mentioning: Small Victories are Urgently … Continue reading ‘City Council holds hearing on pedestrian safety’

Lessons from the latest Ebola outbreak in the DRC

I recently published an editorial in Infectious Diseases News, entitled, “Lessons from the latest Ebola outbreak in the DRC.” Since publishing the editorial, there was a deadly attack in Beni. See Tweets below by Peter Salama and Helen Branswell. Now back to my hiatus from blogging and social media. Continue reading Lessons from the latest Ebola outbreak in the DRC

FDA warns about rare occurrences of a serious infection with SGLT2 inhibitors for diabetes

The U.S. Food and Drug Administration (fda) is warning that cases of a rare but serious infection of the genitals have been reported with the class of type 2 diabetes medicines called sodium-glucose cotransporter-2 (sglt2) inhibitors. This serious rare infection, called necrotizing fasciitis of the perineum, is also referred to as Fournier’s Gangrene. The magnitude of the problem is unclear. What should be done? Please … Continue reading FDA warns about rare occurrences of a serious infection with SGLT2 inhibitors for diabetes